

# Investment Opportunity



**GATC Health**

# Markets—Personalized & Precision Medicine



- PRICEWATERHOUSE COOPERS – Global CPA
- “Precision Medicine and Personalized Medicine – Generating \$286 Billion and Growing 11% Annually”

## Personalized Medicine through Genomics

Per a [Pricewaterhouse Coopers report](#), personalized medicine is already generating \$286 billion per year in revenues and is growing 11% annually.

The economic impact of personalized medicine promises to explode over the next few years.



# GATC Health's Technology

## GATC Health's Hyper-Focused Artificial Intelligence Answers the Most Complex Biological Questions

GATC Health has managed, in a very short time, to productize their technology for consumer markets while expediting drug discovery and development for pharma partners. **GATC focuses on Predictive Multiomics™**, which studies the various biomes, or biological components of the human body (genome, proteome, transcriptome, etc.) to predictively model what may happen when a disease or treatment is given to a virtual, digital human. GATC's platform, **Multiomics Advanced Technology™ (MAT)**, makes Predictive Multiomics possible.

- **In summary**, by analyzing billions of biological data points in minutes, GATC Health can assess individual health risks, recommend treatments, expedite clinical trials and help discover new drugs.



# Proprietary, Patented Intellectual Property

## Purpose-Built Artificial Intelligence for Healthcare

GATC Health's core business is developing and training advanced digital neural networks to "think" like human biology. Competing systems are constrained by linear, mathematical algorithms that struggle to provide medically accurate data to clinicians, researchers, doctors and pharma partners. The company's **patented class-leading Multiomics Advanced Technology™** (MAT) is the basis for all GATC's development projects.

## New Molecule Generator

GATC Health's science and technology teams have fully automated a new process for new molecule discovery. This specific instance of the MAT platform quickly and accurately identifies **new molecules that form the basis for completely new drugs**. The company believes its **patented New Molecule Generator technology is completely unique**.






## Discovery and Treatment "Engines"

The company has productized its MAT platform by creating separate instances that address a specific disease, condition or therapy. To date, the company has **patented 5 consumer-facing Engines**.



# Proof: Our Technology Is More Advanced Than Other Competitors

*As compared to 23andMe, our database is larger, built from multiple clinically relevant sources and capable of creating more impact.*

	 GATC	 23andMe
 Database	Whole Exome: 30 million bps / 60 million bases Whole Genome: 3.2 billion bps or <b>6.4 billion bases</b>	Partial Data: <b>400,000 data points</b>
 Data Sources	Data is from <b>multiple clinically relevant sources</b> , (i.e., transcriptomics, proteomics, soap notes, family history etc.)	<b>Insufficient and consumer reported.</b> Example: self reporting eye color or pain tolerance
 Analytics and Insights	Ability to train neural networks on disease states / incorporate clinically relevant data from partners. GATC is capable of doing more, including drugs discovery and early detection in multiple areas	Internal capabilities / imprecise ancestry report; participates as a passive data source for pharma partners.

Valued at ~\$3.7B, 23andMe is currently losing hundreds of millions of dollars per year. They recently signed a \$300M with GSK to increase their clinical efficiency; GATC can not only replicate these types of agreements, but fully establish ourselves as the leader in the multiomics space.

# Proof: We Have Already Generated Proof of Concept With Our Liquid Biosciences Partnership



## GATC Health and Liquid Biosciences Partner to Improve Drug Development & Precision Medicine Research

*The Collaboration Will Leverage Innovative Technology Platforms to Help Pharma Companies Develop Drugs Faster, More Efficiently and With Higher Success Rates*



### Patent Application Summary

U.S. patent application number 16/938791 was filed with the patent office on 2021-04-08 for *personal wellness recommendation engine*. The applicant listed for this patent is GATC Health Corp. Invention is credited to Christopher Dean, Ian Jenkins, Vaishnavi Narayan.


Additional Patents planned



GATC Health





# Promise: Drug Discovery Process Evolution Driven by GATC Health

*GATC Health delivers one to three actionable drug candidates in 3 - 6 months.*



# Proof: Competitive Landscape and Valuation Suggests Strong Potential for GATC Health

*The recent publicly listed genomics company's market capital aligns with GATC market valuation*

	 Schrodinger	 23andMe	 SOPHiA GENETICS	 GATC			
Market Capital (Listing Date)	<b>\$ 3.936B</b> (Feb 2020)	<b>\$ 3.775B</b> (Jun 21)	<b>\$ 1.139B</b> (Jul 21)	<b>Asset Based Valuation</b>	<b>\$ 1.014B</b> (\$76.02 per share)		
Revenue	<b>\$108.1M</b> (2020)	<b>\$ 306M</b> (2020)	<b>\$10.18M</b> (Q2 21)	Income Approach Valuation	\$ 441M (\$33.08 per share)	Market Based Valuation	\$797M (\$59.75 per share)
Core Business	<ul style="list-style-type: none"> <li>Drug discovery and management service</li> <li>Material design simulation</li> </ul>	<ul style="list-style-type: none"> <li>Personalized healthcare</li> <li>DNA testing for inherited traits</li> <li>Drug discovery</li> </ul>	<ul style="list-style-type: none"> <li>Next generation sequencing</li> <li>Radiomics Imaging AI</li> <li>Genomic data analysis (Proteomics and metabolomics)</li> </ul>	<b>GATC Forecast Revenue 2022</b>	<b>\$26M</b>		



# The Next Generation of Medicine

## Accelerating Drug Discovery & Clinical Trials for Pharma

**NEW MOLECULE GENERATOR:** After trying—and failing—for four years to validate biomarkers for one of our partners, IBM Watson was shown the door. We completed the project in under two months **AND DISCOVERED NEW MOLECULES FOR ADDICTION TREATMENT.** Based on this groundbreaking work, GATC's world-class science and tech teams created an entirely new analytical framework that automates the identification of new or existing molecules used to create drugs. This patented process can potentially **SAVE 20% OR MORE OFF DRUG DISCOVERY TIMELINES** and decisively sets GATC Health apart from others in the field.

**CLINICAL TRIALS, BIOMARKER & EPIGENETICS VALIDATION:** GATC's MAT platform is the perfect partner for Big Pharma. From clinical trial participant pre-screening to data validation, GATC is a new breed of service provider. In addition to the breakthrough **Cocaine Addition** work performed with our partner for a **top five pharma client**, we anticipate working in a similar capacity this year with a number of leading pharma partners on the following:

**Alzheimer's Disease • Parkinson's Disease**

**Major Depressive Disorder • Amyotrophic Lateral Sclerosis (ALS)**



# Promise: Drug Discovery Process Evolution Alt to slide 7

**Traditional Pharmaceutical Drug Discovery is flawed inefficient**



- 5000 Molecules
- 4-6 years

**Competitors are lacking significant improvements**

**SCHRÖDINGER.**

- 1000 Molecules
- 2-3 years

**GATC Health's innovation is cutting-**



- 1-3 Molecules
- Less than 3 months

**One Successful FDA Approved Drug**

# Investment Opportunity

## Regulation A+

- Estimated initial share price: **\$5.00**
- Amount to be raised: \$20 - \$50 million
- Funds will be used for working capital, C-suite buildout and development of additional “engines”
- Valuation expected to be upwardly adjusted during raise in consideration of material events now in negotiations



# Conviction: We Have A Strong Management Team With A Proven Track Record Of Success

## GATC Health Management



### Jeff Moses (President)

- Former CMO of PowerOne Energy Corp
- Multiple C-level positions with growth stage companies
- Founder & creative director of ad agency serving Fortune 500 clients



### Kevin Woodbridge (Executive VP)

- 30+ years in finance and corporate development
- Instrumental in financing hundreds of millions of dollars for various companies



### V. Tyrone Lam (COO)

- Co-founder, COO, First Americans Health & Wellness
- VP Business Development, Predilytics and Welltok



### Ian Jenkins (CSO)

- Founder and CEO of personalized health and nutrition/genetics company, Fréllii, Inc.
- Former researcher with the Human Genome Project



### Jayson Uffens (CTO)

- Founder & CEO, IrisMind, a SaaS platform providing financial institutions with meaningful engagement opportunities
- Former VP at GrubHub

## Scientific Advisors



### Eric J. Mathur (Head of Science Advisory Board)

- Chief Science Officer at Kore Genetics
- Over 35 years in primary and applied biotechnology with a focus on translational science



### Dr. Daniele Piomelli (Science Advisor)

- Louise Turner Arnold Chair in Neurosciences and Professor of Anatomy and Neurobiology, Pharmacology and Biological Chemistry at the University of California Irvine School of Medicine



### Dr. Jonathan Lakey (Science Advisor)

- Professor of Surgery and Biomedical Engineering
- Director of Research and Clinical Islet Program
- Sue and Bill Gross Stem Cell Research Center
- University of California Irvine



### Dr. Jack Lewin (Science Advisor)

- Principal and Founder Lewin and Associates LLC
- Chairman, National Coalition on Health Care, Washington DC
- Former President and CEO of Cardiovascular Research Foundation



### Dr. Chitra Bhakta (Science Advisor)

- Chronic disease specialist
- Physician at OC Integrative Medical Center